电子邮件 | lma***@***.com | 获取Email |
---|
电子邮件 | lma***@***.com | 获取Email |
---|
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo's T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company's ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo's proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital. For more information, please visit www.crescendobiologics.com.
公司 | Crescendo Biologics Limited |
---|---|
职位 | Head of Clinical Operations |
地点 | United Kingdom |
http://www.linkedin.com/in/lis-mable-66b3088 | |
部门 | master_operations |
头衔 | Head of Clinical Operations at Crescendo Biologics |
Crescendo Biologics Limited Head of Clinical Operations
2022-04-01 -
Crescendo Biologics Limited Consultant Project Manager at Crescendo Biologics
2021-08-01 -
Crescendo Biologics Limited Project Manager
2019-07-01 - 2020-01-01
Project Manager
2018-08-01 -
VHSQUARED LIMITED Project Manager
2016-08-01 - 2019-03-01
Lis Mable 在 Crescendo Biologics Limited 担任 Head of Clinical Operations at Crescendo Biologics
Lis Mable 在 Crescendo Biologics Limited 的职位是 Head of Clinical Operations at Crescendo Biologics
Lis Mable 的电子邮件地址是 lma***@***.com
Lis Mable 的电话号码是 -
Lis Mable 的公司电话号码是 +441****
Lis Mable 在 research 工作。
Lis Mable 的一些同事包括Amelia Copas、Chris Wyre、Isabella Ascanio、Colette JohnstonDavide Girolamo、。
Lis Mable联系方式: 电子邮件地址:lma***@***.com 电话号码:-
Lis Mable 的个人领英是:http://www.linkedin.com/in/lis-mable-66b3088
Lis Mable 的办公地点:meditrina babraham research campus #260, babraham, cambridgeshire, united kingdom
全球B2B企业库
海关贸易数据
展销采购数据
Top-ranked on G2 Crowd